Healthcare Industry News: Robotic Catheter
News Release - March 2, 2009
Hansen Medical Announces Strategic Relationship With Advanced Cardiac Therapeutics and Procurement of Certain Exclusive Rights to Its Patented Microwave Radiometry TechnologyMOUNTAIN VIEW, CA--(Healthcare Sales & Marketing Network)--Mar 2, 2009 -- Hansen Medical, Inc. (NasdaqGM:HNSN ) today announced an equity investment in Advanced Cardiac Therapeutics, Inc. (ACT), and the securing of exclusive rights to certain ACT intellectual property for certain robotic applications. ACT, a privately held company located in Laguna Beach, Calif., is developing a novel technology that is designed to accurately measure the temperature in a lesion during cardiac ablation procedures.
ACT's patented Microwave Radiometry System has the potential to be incorporated into standard and irrigated cardiac catheters. A catheter with ACT's technology would have the potential to assist electrophysiologists by providing real-time feedback about effective energy delivery by the catheter. ACT's technology has not been clinically tested and has not received regulatory approval.
In reference to the technology, Paul Wang, M.D., a leading electrophysiologist at Stanford University Medical Center says he believes that, "Accomplishing accurate and real-time temperature sensing has the potential to dramatically improve our ability to create safe, efficacious and persistent lesions."
"Hansen Medical continues to build on the value of flexible robotics technology and we are very pleased to add certain rights to this promising Microwave Radiometry System to our technology portfolio," said Frederic Moll, M.D., founder and chief executive officer, Hansen Medical.
About Hansen Medical
Hansen Medical Inc., based in Mountain View, Calif., develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. Its first product, the SenseiŽ Robotic Catheter system, is a robotic navigation system that enables clinicians to place mapping catheters in hard-to-reach anatomical locations within the heart easily, accurately and with stability during complex cardiac arrhythmia procedures. The Sensei system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data and was cleared by the U.S. Food and Drug Administration (FDA) in May 2007 for manipulation and control of certain mapping catheters in Electrophysiology (EP) procedures. The safety and effectiveness of the Sensei system for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established. In the European Union, the Sensei system is cleared for use during EP procedures, such as guiding catheters in the treatment of AF. Additional information can be found at www.hansenmedical.com.
About Advanced Cardiac Therapeutics, Inc.
Advanced Cardiac Therapeutics, based in Laguna Beach, Calif., was founded in 2007 to develop products and technology using proprietary Microwave Radiometry for use in electrophysiology. Advanced Cardiac Therapeutics is a privately held company.
This press release contains forward-looking statements regarding, among other things, statements relating to expectations, goals, plans, objectives and future events. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements about the expectations regarding new features and applications for the company's products and technology. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause actual results to differ materially from those indicated by forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, the risks and uncertainties inherent in our business, including risks involved in developing new products, risks of adverse or inconclusive results in pre-clinical and clinical trials, risks associated with incorporating ACT's technology into catheters and with other products delays in obtaining or failure to obtain necessary regulatory clearances; potential safety and regulatory issues that could slow or suspend our sales; our ability to effectively sell, service and support our products; the scope and validity of intellectual property rights applicable to our products; competition from other companies; of our systems; and our ability to obtain additional financing to support our operations. These and other risks are described in greater detail under the heading "Risk Factors" contained in our periodic SEC filings, including our Quarterly Report on Form 10-Q filed with the SEC on November 5, 2008. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Hansen Medical, Heart Design, Hansen Medical & Heart Design, Sensei, and IntelliSense are registered trademarks, and Artisan, CoHesion, Fine Force Technology, and Instinctive Motion are trademarks of Hansen Medical, Inc., in the United States and other countries.
Source: Hansen Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.